BR9607757A - Vírus recombinante defectivo adenovírus utilização de um vírus e composição farmacêutica - Google Patents

Vírus recombinante defectivo adenovírus utilização de um vírus e composição farmacêutica

Info

Publication number
BR9607757A
BR9607757A BR9607757A BR9607757A BR9607757A BR 9607757 A BR9607757 A BR 9607757A BR 9607757 A BR9607757 A BR 9607757A BR 9607757 A BR9607757 A BR 9607757A BR 9607757 A BR9607757 A BR 9607757A
Authority
BR
Brazil
Prior art keywords
virus
pharmaceutical composition
defective recombinant
recombinant virus
adenovirus use
Prior art date
Application number
BR9607757A
Other languages
English (en)
Inventor
Patrice Benefle
Martine Latta-Mahieu
Nicolas Duverger
Sandrine Seguret
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of BR9607757A publication Critical patent/BR9607757A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
BR9607757A 1995-03-14 1996-03-12 Vírus recombinante defectivo adenovírus utilização de um vírus e composição farmacêutica BR9607757A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9502943A FR2731710B1 (fr) 1995-03-14 1995-03-14 Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique
PCT/FR1996/000381 WO1996028553A1 (fr) 1995-03-14 1996-03-12 Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisation en therapie genique

Publications (1)

Publication Number Publication Date
BR9607757A true BR9607757A (pt) 1999-01-26

Family

ID=9477007

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9607757A BR9607757A (pt) 1995-03-14 1996-03-12 Vírus recombinante defectivo adenovírus utilização de um vírus e composição farmacêutica

Country Status (15)

Country Link
US (1) US20010014319A1 (pt)
EP (1) EP0815239A1 (pt)
JP (1) JPH11501518A (pt)
KR (1) KR19980703008A (pt)
AU (1) AU711381B2 (pt)
BR (1) BR9607757A (pt)
CA (1) CA2214010A1 (pt)
CZ (1) CZ286897A3 (pt)
FR (1) FR2731710B1 (pt)
HU (1) HUP9801214A3 (pt)
IL (1) IL117466A0 (pt)
NO (1) NO974179D0 (pt)
SK (1) SK124897A3 (pt)
WO (1) WO1996028553A1 (pt)
ZA (1) ZA961998B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017434A2 (en) * 1995-11-09 1997-05-15 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services The use of lecithin-cholesterol acyltransferase (lcat) in the treatment of atherosclerosis
FR2755975B1 (fr) * 1996-11-15 1999-05-07 Rhone Poulenc Rorer Sa Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
WO1998046767A1 (en) 1997-04-11 1998-10-22 Takeda Chemical Industries, Ltd. Proteins having lecithin-cholesterol acyltransferase-like activity, their production and use
US7737861B2 (en) * 2001-06-19 2010-06-15 Paxflow Holdings Pte Ltd. Location, communication and tracking systems
SI1541674T1 (sl) 2002-06-18 2011-04-29 Eisai R&D Man Co Ltd Primarno kultivirani adipociti za gensko terapijo
EP2037740A4 (en) * 2006-06-07 2011-12-28 Reddys Lab Ltd Dr COMPOSITIONS AND METHODS FOR IMPROVING THE REVERSE CHOLESTER INTRANSPORT
ES2376396T3 (es) 2006-06-26 2012-03-13 Amgen Inc. Método para tratar aterosclerosis.
WO2008108344A1 (ja) * 2007-03-02 2008-09-12 Cellgentech, Inc. Ｌｃａｔ欠損症の遺伝子治療用細胞並びにこれを産生するのに用いられる複製欠損性レトロウイルスベクター及びプラスミド
JP6951429B2 (ja) 2016-09-20 2021-10-20 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ 新規のブタインフルエンザワクチン
CA3036293A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh New promoters
US10329586B2 (en) 2016-09-20 2019-06-25 Boehringer Ingelheim Vetmedica Gmbh Canine adenovirus vectors
BR112019005516A2 (pt) 2016-09-20 2019-06-18 Boehringer Ingelheim Vetmedica Gmbh novo sítio de inserção do ehv orf70

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8424757D0 (en) * 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
US5049488A (en) * 1985-11-08 1991-09-17 Genentech, Inc. Method and nucleic acid for the preparation of lecithin:cholesterol acyltransferase
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
WO1995002697A1 (fr) * 1993-07-13 1995-01-26 Rhone-Poulenc Rorer S.A. Vecteurs adenoviraux defectifs et utilisation en therapie genique

Also Published As

Publication number Publication date
CZ286897A3 (en) 1997-12-17
FR2731710A1 (fr) 1996-09-20
MX9706569A (es) 1997-11-29
KR19980703008A (ko) 1998-09-05
WO1996028553A1 (fr) 1996-09-19
IL117466A0 (en) 1996-07-23
HUP9801214A2 (hu) 1998-08-28
NO974179L (no) 1997-09-10
JPH11501518A (ja) 1999-02-09
AU5008296A (en) 1996-10-02
CA2214010A1 (fr) 1996-09-19
EP0815239A1 (fr) 1998-01-07
SK124897A3 (en) 1998-02-04
ZA961998B (en) 1996-09-26
AU711381B2 (en) 1999-10-14
FR2731710B1 (fr) 1997-04-30
NO974179D0 (no) 1997-09-10
US20010014319A1 (en) 2001-08-16
HUP9801214A3 (en) 2000-08-28

Similar Documents

Publication Publication Date Title
BR9607317A (pt) Peptídios e composição farmacêutica
BR9607318A (pt) Peptidos e composição farmacêutica
BR9510090A (pt) Utilização de um adenovírus recombinante
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
EE200000232A (et) Farmatseutiline kompositsioon ja selle kasutamine
BR9604632A (pt) Compostos bicíclicos aromáticos utilizaçao de pelo menos um dos compostos composiçao farmacêutica composiçao cosmética e utilizaçao de uma composiçao cosmética
DE69727559D1 (de) Enterisch überzogene pharmazeutische zusammensetzungen von mycophenolat
BR1100824A (pt) Composto e composição farmacêutica
IL122347A0 (en) Recombinant adenovirus and adeno-associated virus cell lines methods of production and pharmaceutical compositions containing the same
BR9706311A (pt) Compostos de estilbeno composição farmacêutica composição cosmética e uso de uma composição cosmética
EE04440B1 (et) Kaparetseptori opioidpeptiidid ja farmatseutilinekompositsioon
BR9504791B1 (pt) composto de polipeptìdeo e composição farmacêutica.
DE69626397D1 (de) Darifenacin enthaltende pharmazeutische zubereitungen
BR9607757A (pt) Vírus recombinante defectivo adenovírus utilização de um vírus e composição farmacêutica
EE9600139A (et) Farmatseutilised preparaadid ja ravimid endoteelsete düsfunktsioonide vältimiseks ja raviks
EE04119B1 (et) Külmkuivatamiseks sobiv ravimkoostis ja selle valmistamise meetod
BR9509688A (pt) Composto e composição farmacêutica
BR9708790A (pt) Composto uso de um composto e formulação farmacêutica
BR9507451A (pt) Composição farmacêutica uso de uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo e produto contendo uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo
FI973229A0 (fi) Uusi farmaseuttinen koostumus
BR9604938A (pt) Vírus recombinante deficiente utilização deste vírus composição farmacêutica e célula de mamífero
EE9900578A (et) Tisoksaniidi ja nitasoksaniidi farmatseutilised kompositsioonid
BR9710568A (pt) Composi- o farmac-utica contendo um antagonista 5Hht2c e um antagonista d2
BR9509055A (pt) Imidazoloquinoxalinona uso da mesma e composiçao farmacêutica
DE69725166D1 (de) Substituierte benzamidderivate und diese enthaltende pharmazeutische zusammensetzung

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements